Pivmecillinam
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Pivmecillinam: From Antibacterial Therapy to Acute Bronchitis
One-Sentence Summary
Pivmecillinam is the oral prodrug of mecillinam, an amidinopenicillin-class antibacterial agent; its specific original indication is not recorded in the available data. The TxGNN model predicts it may be effective for acute bronchitis (including exacerbations of chronic bronchitis), supported by 9 historical publications — predominantly randomised controlled trials from the 1970s–1990s — though no clinical trials are currently registered for this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the evidence pack. Pivmecillinam is an amidinopenicillin-class antibacterial; no UK marketing authorisation or indication text is available |
| Predicted New Indication | Acute bronchitis |
| TxGNN Prediction Score | 95.85% |
| Evidence Level | L2 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Pivmecillinam is the oral prodrug of mecillinam, an amidinopenicillin-class antibacterial with activity against Gram-negative bacteria. A structured mechanism-of-action entry is not available in this evidence pack (flagged as a data gap, with a DrugBank API lookup recommended as remediation), but class-level pharmacology is supported by the prediction rationale accompanying this candidate.
The drug’s original indication is not recorded in the available data — no original indications or UK marketing authorisations are listed. However, an extensive body of historical literature, drawn from general-practice and hospital studies of respiratory tract infections, shows pivmecillinam (typically combined with pivampicillin as the product “Miraxid”) has long been studied for acute exacerbations of chronic bronchitis and related lower respiratory tract infections.
Mechanistically, exacerbations of chronic bronchitis are frequently driven by Gram-negative organisms such as Haemophilus influenzae, against which pivmecillinam/mecillinam has known activity — making the TxGNN prediction biologically plausible. It should be noted that almost all of the supporting literature reflects the fixed combination product (pivmecillinam + pivampicillin) rather than pivmecillinam monotherapy, which should be factored into any assessment of evidence strength.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6312461 | 1983 | RCT | Pharmatherapeutica | Double-blind trial (n=62) in chronic bronchitis exacerbations: pivmecillinam+pivampicillin achieved an 88% satisfactory clinical response versus pivampicillin alone |
| 330483 | 1977 | RCT | J Antimicrob Chemother | 132 patients with purulent exacerbations of chronic bronchitis; combined pivmecillinam+amoxycillin significantly improved sputum conversion to mucoid by day 7 versus amoxycillin alone |
| 6334071 | 1984 | RCT | J Antimicrob Chemother | 49 hospitalised patients with acute exacerbations of chronic bronchitis; pivmecillinam/pivampicillin (72% success) was clinically equivalent to co-trimoxazole (70%), with better sputum pus eradication (84% vs 74%) |
| 3930309 | 1985 | RCT | J Int Med Res | 408 patients with respiratory tract infections (including acute bronchitis); Miraxid compared with a triple tetracycline combination (Deteclo) in general practice |
| 3533674 | 1986 | RCT | J Int Med Res | 388 patients with lower respiratory tract infections (acute bronchitis and exacerbations of chronic bronchitis); Miraxid compared with amoxycillin/clavulanate (Augmentin) |
| 3556261 | 1987 | RCT | J Int Med Res | 3,783 general practice patients with acute exacerbations of chronic bronchitis; pivmecillinam/pivampicillin produced significantly more “excellent” responses than amoxycillin, with no difference in overall response rate |
| 2218422 | 1990 | RCT | Scand J Infect Dis Suppl | 84 patients with purulent exacerbations of chronic bronchitis; pivampicillin achieved comparable bacteriological (94–97%) and clinical cure (97%) rates to ofloxacin, though with more adverse reactions |
| 3907987 | 1985 | Cohort | Curr Med Res Opin | 318 general practice patients with respiratory tract infections including acute bronchitis; Miraxid compared with co-trimoxazole across four diagnostic strata |
| 4070323 | 1985 | Cohort | Pharmatherapeutica | 350 general practice patients with respiratory tract infections including acute bronchitis; Miraxid compared with amoxycillin, with no difference in overall clinical outcome at 7 days |
UK Market Information
No UK marketing authorisations are recorded for pivmecillinam in the evidence pack; the product is currently not marketed in the UK.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Warnings, contraindications and drug interaction data for pivmecillinam are currently unavailable and are flagged as a blocking data gap requiring MHRA/SmPC lookup before safety review can proceed.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: There is a substantial body of historical RCT-level literature (9 publications, 1977–1990) supporting antibacterial efficacy in acute bronchitis and exacerbations of chronic bronchitis, but no modern or currently registered clinical trials exist for this indication, and critical drug-level safety data (warnings, contraindications, interactions) is entirely missing — a blocking gap that must be resolved before formal safety evaluation.
To proceed, the following is needed:
- UK/MHRA SmPC and BNF safety data (warnings, contraindications, drug interactions) — currently a blocking data gap
- Formal mechanism-of-action confirmation via DrugBank API
- Clarification of whether pivmecillinam monotherapy evidence applies, given most literature reflects the pivmecillinam + pivampicillin combination product (Miraxid)
- Consideration of more recent clinical evidence, as the existing literature base predates 1990
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.